Clinical Trial Update: A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of ramucirumab plus paclitaxel and carboplatin in non-small cell lung cancer completed, with results posted on 2014-12-29.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-12-29